Centessa Pharmaceuticals
15.32
0.48 (3.23%)
At close: Jan 15, 2025, 9:44 AM

Centessa Pharmaceuticals Statistics

Share Statistics

Centessa Pharmaceuticals has 131.66M shares outstanding. The number of shares has increased by 33.29% in one year.

Shares Outstanding 131.66M
Shares Change (YoY) n/a
Shares Change (QoQ) 16.33%
Owned by Institutions (%) n/a
Shares Floating 90.14M
Failed to Deliver (FTD) Shares 221
FTD / Avg. Volume 0.04%

Short Selling Information

The latest short interest is 3.63M, so 2.76% of the outstanding shares have been sold short.

Short Interest 3.63M
Short % of Shares Out 2.76%
Short % of Float 4.03%
Short Ratio (days to cover) 4.92

Valuation Ratios

The PE ratio is -5.07 and the forward PE ratio is -9.94.

PE Ratio -5.07
Forward PE -9.94
PS Ratio 111.71
Forward PS 515.8
PB Ratio 3.24
P/FCF Ratio -4.77
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Centessa Pharmaceuticals has an Enterprise Value (EV) of 722.13M.

EV / Earnings -4.78
EV / Sales 105.37
EV / EBITDA -4.35
EV / EBIT -4.22
EV / FCF -4.5

Financial Position

The company has a current ratio of 8, with a Debt / Equity ratio of 0.32.

Current Ratio 8
Quick Ratio 8
Debt / Equity 0.32
Total Debt / Capitalization 24.27
Cash Flow / Debt -2.12
Interest Coverage -17.29

Financial Efficiency

Return on equity (ROE) is -0.64% and return on capital (ROIC) is -45.79%.

Return on Equity (ROE) -0.64%
Return on Assets (ROA) -0.42%
Return on Capital (ROIC) -45.79%
Revenue Per Employee 90.17K
Profits Per Employee -1.99M
Employee Count 76
Asset Turnover 0.02
Inventory Turnover 0

Taxes

Income Tax -25.06M
Effective Tax Rate 0.14

Stock Price Statistics

The stock price has increased by 102.88% in the last 52 weeks. The beta is 1.48, so Centessa Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.48
52-Week Price Change 102.88%
50-Day Moving Average 16.84
200-Day Moving Average 12.92
Relative Strength Index (RSI) 37.23
Average Volume (20 Days) 552.49K

Income Statement

In the last 12 months, Centessa Pharmaceuticals had revenue of 6.85M and earned -151.09M in profits. Earnings per share was -1.57.

Revenue 6.85M
Gross Profit 6.85M
Operating Income -171.28M
Net Income -151.09M
EBITDA -166.07M
EBIT -171.28M
Earnings Per Share (EPS) -1.57
Full Income Statement

Balance Sheet

The company has 128.03M in cash and 84.59M in debt, giving a net cash position of 43.44M.

Cash & Cash Equivalents 128.03M
Total Debt 84.59M
Net Cash 43.44M
Retained Earnings -752.95M
Total Assets 609.72M
Working Capital 541.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -160.34M and capital expenditures -169.00K, giving a free cash flow of -160.51M.

Operating Cash Flow -160.34M
Capital Expenditures -169.00K
Free Cash Flow -160.51M
FCF Per Share -1.67
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -2.50K% and -2.20K%.

Gross Margin 100%
Operating Margin -2.50K%
Pretax Margin -2.57K%
Profit Margin -2.20K%
EBITDA Margin -2.42K%
EBIT Margin -2.50K%
FCF Margin -2.34K%

Dividends & Yields

CNTA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -10.6%
FCF Yield -8.23%
Dividend Details

Analyst Forecast

The average price target for CNTA is $27, which is 82.3% higher than the current price. The consensus rating is "Buy".

Price Target $27
Price Target Difference 82.3%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score 10.21
Piotroski F-Score 3